Journal
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
Volume 97, Issue 4, Pages 1543-1552Publisher
SPRINGER
DOI: 10.1007/s00253-012-4416-2
Keywords
Bacillus Calmette-Guerin; Recombinant BCG; Superficial bladder cancer; Antitumor activity
Categories
Funding
- Brazilian funding agency: Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
- Brazilian funding agency: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Brazilian funding agency: Fundacao de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS)
Ask authors/readers for more resources
BCG therapy remains at the forefront of immunotherapy for treating patients with superficial bladder cancer. The high incidence of local side effects and the presence of non-responder diseases have led to efforts to improve the therapy. Hence, we proposed that an auxotrophic recombinant BCG strain overexpressing Ag85B (BCG a dagger leuD/Ag85B), could enhance the cytotoxicity to the human bladder carcinoma cell line 5637. The rBCG was generated using an expression plasmid encoding the mycobacterial antigen Ag85B to transform a BCG a dagger leuD strain. The inhibitory effect of BCG a dagger leuD/Ag85B on 5637 cells was determined by the MTT method, morphology observation and a LIVE/DEAD assay. Gene expression profiles for apoptotic, cell cycle-related and oxidative stress-related genes were investigated by qRT-PCR. Bax, bcl-2 and p53 induction by BCG a dagger leuD/Ag85B treatment was evaluated by Western blotting. BCG a dagger leuD/Ag85B revealed a superior cytotoxicity effect compared to the control strains used in this study. The results showed that the expression level of pro-apoptotic and cell cycle-related genes increased after BCG a dagger leuD/Ag85B treatment, whereas the mRNA levels of anti-apoptotic genes decreased. Interestingly, BCG a dagger leuD/Ag85B also increased the mRNA level of antioxidant enzymes in the bladder cancer cell line. Bax and p53 proteins levels increased following treatment. In conclusion, these results suggest that treatment with BCG a dagger leuD/Ag85B enhances cytotoxicity for superficial bladder cancer cells in vitro. Therefore, rBCG therapy may have potential benefits in the treatment of bladder cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available